US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Microbot Medical Inc. - Common Stock
(NQ:
MBOT
)
1.160
-0.040 (-3.33%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Microbot Medical Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Microbot Medical® Highlights Growth Strategy
September 25, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
August 11, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
July 21, 2026
Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech...
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
July 07, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
June 30, 2026
Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
June 25, 2026
Innovative Start-Up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
June 23, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
June 16, 2026
The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans...
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
June 09, 2026
First Midwest-based account reflects continued execution of the Company's Full Market Release strategy and expansion into additional U.S. territories
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
June 02, 2026
A leading academic center becomes the first user in the Southeast, Mid-Atlantic region
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
May 26, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
May 15, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
May 14, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
May 05, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
April 30, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
April 22, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
April 14, 2026
The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
April 13, 2026
Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular...
From
Microbot Medical Inc.
Via
GlobeNewswire
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
March 26, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
March 24, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® to Participate at the 38th Annual Roth Conference
March 17, 2026
Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in April
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
March 10, 2026
Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
March 04, 2026
LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
March 03, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
February 24, 2026
Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced Robotics
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference
February 19, 2026
Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular Space
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
February 12, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
February 05, 2026
Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
January 12, 2026
From
Microbot Medical Inc.
Via
GlobeNewswire
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
November 26, 2025
Adoption of LIBERTY is Consistent with Emory’s Commitment to the Growing and Evolving Field of Interventional Radiology
From
Microbot Medical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
